大剂量化疗联合自体干细胞移植对比非清髓巩固治疗初治原发性中枢神经系统淋巴瘤(MATRix/IELSG43):随机3期试验
这项开放标签随机3期试验在5个欧洲国家56家医院纳入初治免疫功能正常的B细胞PCNSL患者(18-65岁不限ECOG,或66-70岁ECOG 0-2),排除中枢外淋巴瘤表现及先天/获得性免疫缺陷。患者接受4周期MATRix诱导(利妥昔单抗+大剂量阿糖胞苷+塞替派+大剂量甲氨蝶呤),达至少部分缓解者1:1随机接受2周期R-DeVIC(利妥昔单抗+地塞米松+依托泊苷+异环磷酰胺+卡铂)或卡莫司汀+塞替派HCT-ASCT。78% vs 51%)。结论支持HCT-ASCT作为适合患者首选巩固策略。
要点
- 初治B细胞PCNSL完成4周期MATRix诱导并达至少部分缓解后,随机接受HCT-ASCT(卡莫司汀+塞替派)或2周期R-DeVIC巩固。
- 巩固后致死性严重不良事件:HCT-ASCT组5例(感染4例、肺栓塞1例),R-DeVIC组2例(均为急性髓系白血病)。
- 适用人群为18-65岁不限ECOG或66-70岁ECOG 0-2的初治免疫功能正常B细胞PCNSL,排除中枢外淋巴瘤表现及免疫缺陷。
适用人群与场景
- 初治、免疫功能正常的B细胞PCNSL患者,年龄18-65岁不限ECOG体力状态,或66-70岁且ECOG体力状态0-2。
- 允许入组前使用糖皮质激素。
- 排除中枢外淋巴瘤表现者,以及先天性或获得性免疫缺陷者。
- 场景为具备移植条件的大学医院及学术性非大学医院,共5个欧洲国家56家中心。
诊断标准与关键阈值
- 入组后先接受4周期MATRix诱导方案(利妥昔单抗、大剂量阿糖胞苷、塞替派,加用大剂量甲氨蝶呤)。
- 诱导后达到至少部分缓解者方可1:1随机进入巩固治疗。
- 原文未提及具体的影像学或评分缓解判定界值。
处置流程与药物剂量
- 第一步:4周期MATRix诱导(利妥昔单抗、大剂量阿糖胞苷、塞替派、大剂量甲氨蝶呤),具体剂量原文未提及。
- 第二步:达至少部分缓解者随机1:1分配至HCT-ASCT组或R-DeVIC组。
- 第三步(HCT-ASCT组):接受含卡莫司汀和塞替派的HCT-ASCT巩固,具体剂量、给药途径及疗程原文未提及。
- 第三步(R-DeVIC组):接受2周期R-DeVIC巩固(利妥昔单抗+地塞米松+依托泊苷+异环磷酰胺+卡铂),具体剂量、给药途径原文未提及。
- 原文未提及巩固治疗的具体目标值或剂量调整方案。
红旗征与不能漏的情况
- 巩固治疗后致死性严重不良事件:HCT-ASCT组5例(感染及侵染4例、肺栓塞1例),R-DeVIC组2例(均为急性髓系白血病)。
- 除肺栓塞外,上述致死性严重不良事件均被判定为可能与治疗相关。
研究设计与关键结果
- 研究类型:开放标签、随机、3期试验;5个欧洲国家56家中心;2014年7月16日至2019年8月31日入组。
- 样本量:入组368例,346例(94%)开始诱导治疗,230例随机,229例纳入分析(R-DeVIC组115例,HCT-ASCT组114例)。
- 结论:在完成诱导治疗的患者中,HCT-ASCT较非清髓巩固显著改善PFS和总生存,被确立为适合患者的首选巩固策略。
证据类型、等级与局限
- 证据类型:随机对照3期试验(RCT),开放标签设计。
- 原文未给出正式证据等级或推荐强度分级。
- 局限:开放标签;原文未提及盲法;纳入分析229例,样本量有限;仅纳入免疫功能正常且符合年龄/ECOG条件者,结论不能外推至排除人群。
对床旁实践的改变
- 对完成MATRix诱导并达至少部分缓解的适合初治B细胞PCNSL患者,HCT-ASCT应作为首选巩固策略而非非清髓R-DeVIC。
- 不适用于中枢外淋巴瘤表现者、先天或获得性免疫缺陷者,以及年龄/ECOG不符合入选条件者。
- 原文未提及具体药物剂量,床旁实施应按所在中心移植方案执行,不能从本研究推断通用剂量。
指南或共识出处
- MATRix/IELSG43随机3期试验(ClinicalTrials.gov NCT02531841;EudraCT 2012-000620-17),发表于Lancet。
- 资助:German Federal Ministry of Research, Technology and Space;Swiss Cancer Research Foundation;Riemser Pharma。
以上提炼依据论文摘要(全文未开放获取,或许可不允许翻译转载);全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Consolidation therapy for primary CNS lymphoma (PCNSL) includes high-dose chemotherapy with autologous stem-cell transplantation (HCT-ASCT), yet its efficacy compared with non-myeloablative chemoimmunotherapy remains uncertain. This study aimed to provide randomised comparative evidence on the efficacy and safety of thiotepa-based HCT-ASCT versus non-myeloablative R-DeVIC consolidation after uniform MATRix induction in newly diagnosed PCNSL.
METHODS: This open-label, randomised, phase 3 trial was conducted across 56 university and academic non-university hospitals with established transplantation facilities in five European countries. Eligible for inclusion were untreated, immunocompetent patients with B-cell PCNSL, aged 18-65 years regardless of Eastern Cooperative Oncology Group (ECOG) performance status, or 66-70 years with ECOG performance status 0-2. Pretreatment corticosteroids were permitted. Exclusion criteria included lymphoma manifestation outside the CNS, and congenital or acquired immunodeficiency. Patients received four cycles of MATRix induction (comprising rituximab, high-dose cytarabine, and thiotepa, in addition to high-dose methotrexate). Patients reaching at least partial response were randomly assigned (1:1) to two cycles of R-DeVIC (rituximab plus dexamethasone, etoposide, ifosfamide, and carboplatin) or HCT-ASCT with carmustine and thiotepa. The primary endpoint was progression-free survival, assessed in the full analysis set (excluding patients with major violations of entry criteria). The safety analysis set contained all randomised patients who initiated therapy. This study is registered with ClinicalTrials.gov (NCT02531841) and the EU Clinical Trials Register (EudraCT number 2012-000620-17). The study is completed.
FINDINGS: Between July 16, 2014, and Aug 31, 2019, 368 patients were enrolled. 346 (94%) patients started induction treatment, and 230 were randomly assigned; 229 patients were analysed (R-DeVIC group, n=115; HCT-ASCT group, n=114). After a median follow-up of 45·3 months, 3-year progression-free survival was significantly superior in the HCT-ASCT group (hazard ratio 0·43 [95% CI 0·27-0·68]; p=0·0003). The 3-year progression-free survival was 78% (95% CI 69-85) in the HCT-ASCT group compared with 51% (41-60) in the R-DeVIC group. The mean number of adverse events per patient was 9·3 (SD 4·4) in the R-DeVIC group and 14·6 (5·8) in the HCT-ASCT group. Fatal serious adverse events following consolidation treatment occurred in two patients in the R-DeVIC group (both acute myeloid leukaemia) and in five patients in the HCT-ASCT group (infections and infestations [n=4], pulmonary embolism [n=1]); all of these events apart from the pulmonary embolism were judged to be possibly related to treatment.
INTERPRETATION: In the largest randomised trial in untreated PCNSL to date, HCT-ASCT significantly improved progression-free and overall survival compared with non-myeloablative consolidation in patients who had completed induction treatment, establishing it as the preferred consolidation strategy in fit patients.
FUNDING: German Federal Ministry of Research, Technology and Space; Swiss Cancer Research Foundation; and Riemser Pharma.
参考来源
- Illerhaus G, Ferreri AJM, Wendler J, et al. High-dose chemotherapy followed by autologous stem-cell transplantation versus non-myeloablative consolidation in primary CNS lymphoma (MATRix/IELSG43): a randomised phase 3 trial. Lancet. 2026. PMID: 42486133. doi:10.1016/S0140-6736(26)00917-7
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。